insights_auto
Why is RARE down 3,19%?
Dive Deeperchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
14,74 $
arrow_downward
-3,19%(-0,49) 1D
5 հոկ, 13:04:02 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
15,25 $
High
15,31 $
Low
14,21 $
Mkt. cap
1,45 մլրդ
Avg. vol.
5,73 մլն
Volume
1,45 մլն
52-wk high
39,89 $
52-wk low
12,73 $
EPS
-5,84 $
Beta
0,35
Shares outstanding
98,59 մլն
No. of employees
1 հզր
Open
15,25 $
High
15,31 $
Low
14,21 $
Mkt. cap
1,45 մլրդ
Avg. vol.
5,73 մլն
Volume
1,45 մլն
52-wk high
39,89 $
52-wk low
12,73 $
EPS
-5,84 $
Beta
0,35
Shares outstanding
98,59 մլն
No. of employees
1 հզր
News stories
From web sources and news partners
MarketBeat
·
35 րոպե առաջ
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6% - Here's Why
AD HOC NEWS
·
8 ժամ առաջ
RARE stock gained 3.19 percent after FAYUVI approval
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1,37 հզր
Founded2010
HeadquartersNovato, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websiteultragenyx.com